PRIMARY STUDY
Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.
Key Findings: Findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives are required before definitive conclusions can be drawn.
Type of Study: Clinical Trial
Study Sample Size: 21
Study Result: Positive
Study Location(s): Brazil
Year of Pub: 2014
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Sub-Ratio: 0:1 (THC:CBD)
Dosage: Three study groups: CBD (75 mg/day), CBD (300 mg/day), or placebo
Link to study
